Scenarios and Signposts

Scenarios and Signposts

Figures converted from Indonesian rupiah (IDR) at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged. Per-share and valuation figures are converted at the 15 July 2026 rate; full-year flows at their period-end rates.

The report's other chapters price CPIN's parts in isolation. Read together, the case is most sensitive to a single arithmetic choice — which earnings figure belongs under the $0.169 price — and it has three plausible answers. At the record FY2025 base the stock is cheap; at the mid-cycle earnings the last decade actually delivered it is roughly fair; at a downstream trough it is dear. The pivot across all three is the broiler spread CPIN does not set, and the market, at 8.9x the record, already prices the middle answer.

The denominator carries the debate

The valuation argument depends on which earnings number belongs under the price. CPIN earned a record $339m net profit in FY2025, or $0.0189 per share [1]. But the same per-share line has printed $0.0078 in the FY2023 trough and averaged about $0.0123 across the last six years — a 2.4x span between the low and the peak. At $0.169 the stock is 8.9x the record, 7.5x an inflated trailing figure, and 11–14x the mid-cycle earnings the business has actually generated.

Source: FY2025 EPS $0.0189 as reported [2]; trough, average, and normalized bases derived from reported FY2020–FY2025 financials (Pricing the Cycle).

The record was efficiency-driven, not a price spike — the broiler segment's result rose 64.9% even as its average selling price fell [3], and processed chicken swung from a $4.8m loss to a $52m profit on lower cost of goods [4]. Efficiency can persist, which makes the record higher-quality than a spot-price windfall. But the level still sits on an industry spread that put the same broiler line into a loss in FY2023, when feed alone produced 104% of the group's segment result and the downstream lost money [5]. Which basis is right decides whether the ~33% de-rating from the January 2026 high is an opportunity or a correct call.

At $0.169 CPIN trades at 8.9x record FY2025 EPS but about 14x its own ten-year-average EPS, and the record it is measured against was made entirely downstream — broiler result rose 64.9% to $201m while feed slipped to $231m — so the low multiple is a peak, downstream-driven denominator rather than a discount to normalized value. [6]

Three scenarios

The scenarios below hold the framework simple: an earnings basis, a valuation method matched to it, and a resulting fair-value range. All three apply the same modest control-and-royalty discount established in Control and Related Parties — a 12–13x multiple rather than the 13–14x the market historically paid the average earnings, reflecting the near-fixed $43m brand royalty [7] and a family-controlled structure whose intra-group terms are disclosed but not independently repriced.

Current price $0.169 (15 Jul 2026) sits at the mid-cycle midpoint. Source: derived from reported FY2020–FY2025 financials and book value (Pricing the Cycle); scenario framework as described.

Source: derived from reported financials — FY2025 segment results [8], equity of $1.88bn (book value $0.115/share) [9]; scenario framework and multiples as described.

Reverts to mid-cycle is the neutral. Applying 12–13x to the $0.012–0.015 the business earns on average puts fair value at roughly $0.149–0.198 — a band whose midpoint, near $0.173, is within a few percent of where the shares trade. The de-rating has repriced the stock from the peak toward the average, not to a discount against normalized value.

Spread holds elevated is the bull, and it is where consensus sits: capitalize a base near the record or trailing figure and fair value runs to about $0.226–0.292, bracketing the ~$0.275 one-year consensus and the street's higher DCF-based marks near $0.325. This requires two things to hold together — the FY2025 efficiency gains proving durable, and the demand floor from the government's Free Nutritious Meals (MBG) programme translating into CPIN volume. Q1 2026 net profit of $142m, up about 67%, is consistent with the base extending [10], though the growth was concentrated upstream — day-old chicks up 77.6% and feed up 28.4% against broiler up only 3.7% [11], and Q1 carries a Ramadan lift.

Downstream troughs is the bear. If oversupply returns and the downstream reverts to loss as it did in FY2023, per-share earnings fall toward $0.0078 and the stock is better valued off book than off a depressed multiple: at 1.0–1.2x the $0.115 book value, roughly $0.116–0.138, or about 19–32% below spot. The downside is real but cushioned — CPIN has posted no loss year since FY2020 and runs a net-cash balance sheet [12]. The offsetting risk is that a trough compresses the book itself: biological assets plus inventories are about $1.0bn, roughly 36% of total assets, and are carried on the same cyclical chicken and feed prices [13].

On the numbers the payoff is asymmetric toward the upside — roughly +34% to +73% if the elevated base holds against about −19% to −32% if the spread troughs, with the neutral outcome near today's price. The weighting, though, rests on the forward broiler spread, which the filings cannot show, and the one new structural support the bull leans on is real in aggregate but unquantified for CPIN — its sizing and the November 2024 counter-signal are set out in The 2026 Evidence. What would move the read is direct: a live-bird price that sustains above the government reference floor, and a first disclosed MBG-linked revenue line.

The tension, as shared facts

Each row is a fact both sides accept; they disagree on what it implies and on what would settle it.

Sources: FY2025 broiler result and pricing [14]; Q1 2026 segment detail [15]; FY2023 trough segments [16]; FY2025 capex [17]. MBG figures per Indonesia's National Nutrition Agency, as reported.

The rows are not symmetric. Feed is the settled part of the case — a cross-cycle earner that has never posted a loss year — and it makes the downside survivable rather than existential (Feed Economics). The moat is proven where it operates, in an 8.0% net margin against Malindo's 3.1% in the same year (Competitive Moat), but it protects the stable feed and breeding base, not the government-managed downstream spread. The recovery is also not universal: peer PT Widodo Makmur Unggas booked a FY2025 net loss on weak purchasing power [18], a reminder that scale and integration, not sector membership, earned CPIN's result.

What to watch

Each item names a line, where it prints, the threshold that changes the read, and which way a surprise cuts.

Sources: feed floor and segment results [19]; FY2025 capex [20]; royalty [21]; FY2025 dividend of $177m / $0.010 per share [22]. Live-bird price and MBG figures per government and program data, as reported.

The single most useful of these is the first: the farm-gate live-bird price against the government's reference. It is the direct reading of the spread that the segment revenue lines can only proxy, it prints weekly rather than quarterly, and it is the variable that moves the earnings basis — and therefore the scenario — more than any other. That makes it the highest-value swing signal in the case, though not the whole of it: the feed floor, at 104% of the group's segment result in the FY2023 trough [23], bounds the downside whatever the spread does.